MIR205 (MicroRNA 205)

Collectively, our findings suggest that SPI1 palmitoylation inhibits c-CBL-mediated ubiquitination and degradation, thereby enhancing SPI1 protein stability and its transcriptional regulation of miR-205-5p. Upregulated miR-205-5p in NPC cells is packaged into exosomes and transferred to endothelial cells, where it targets and inhibits WWC2 expression, eventually promoting angiogenesis and NPC radioresistance.

The results suggest that miR-205, FGF2, and CARMA3 may serve as potential biomarkers for the identification of colorectal cancer (CRC), particularly when used in multi-marker panels to improve diagnostic accuracy. Their clinical utility should be confirmed through additional validation in larger cohorts.

Overall, current evidence supports miRNAs as promising diagnostic, prognostic, and predictive biomarkers in cutaneous oncology. Standardized methodologies and large-scale validation remain essential for their integration into routine clinical practice.

These miRNAs may serve as a potential diagnostic, prognostic, and therapeutic biomarkers for skin cancer. Future studies are needed to improve methods for FFPE analysis and to validate the key differences in miRNA signatures involved in skin cancer development.

Its application in EV‑based therapy could represent an innovative strategy for treating vascular disorders. However, further studies are needed to fully understand its mechanisms of action and optimize its clinical application.

Moreover, combining cisplatin treatment with miR-205 overexpression abolished the clonogenic potential in LMSCC-03 cells. Our study reveals, for the first time, that miR-205 can be an alternative for sensitization to treatment with genotoxic agents, opening a new and promising strategy for highly malignant HNSCC and overcoming cisplatin resistance.

This integrated transcriptomic and miRNA profiling study reveals subtype-specific dysregulation of MAPK-associated genes and their miRNA regulators in BC, with TNBC exhibiting the most profound alterations. These findings provide insight into potential targets for personalized therapeutic strategies.

Pathway enrichment linked these deregulated miRNAs to key oncogenic networks, particularly PI3K/AKT/mTOR, Wnt/β-catenin, and EMT regulation, demonstrating conserved molecular mechanisms shared with human BC and highlighting their potential as biomarkers in CMTs. These findings provide insights into the molecular mechanisms of CMT adenocarcinoma and suggest the potential of miRNA-based biomarkers for the diagnosis and treatment of CMTs.

Furthermore, breast cancer cell-derived exosomes deliver MIR4435-2HG to TAMs, promoting M2 polarization through C/EBPβ activation, which further exacerbates cancer progression. Collectively, our findings unveil a novel MIR4435-2HG/miR-205-5p/UBE2N ceRNA network that drives breast cancer progression and highlights exosomal MIR4435-2HG as a critical mediator of TAM polarization, offering potential as a potential biomarker and therapeutic target for breast cancer.

Pathway analysis via the Kyoto Encyclopedia of Genes and Genomes (KEGG) highlighted critical signalling pathways involved in CCa oncogenesis. In conclusion, theophylline demonstrates cytotoxicity in CCa cells, suggesting its potential for repurposing in CCa theranostics, though further optimization is necessary.

This four-phase study suggests that exosomal miRNA panels have potential diagnostic value for early-stage lung cancer. The UDR platform enabled the selection of a four-miRNA panel (miR-150-5p, miR-301b-3p, miR-369-3p, and miR-497-5p), with bioinformatics analyses providing supportive evidence.